CN103908465A - 一种易于溶出的齐多拉米双夫定片及其制备方法 - Google Patents
一种易于溶出的齐多拉米双夫定片及其制备方法 Download PDFInfo
- Publication number
- CN103908465A CN103908465A CN201210598061.3A CN201210598061A CN103908465A CN 103908465 A CN103908465 A CN 103908465A CN 201210598061 A CN201210598061 A CN 201210598061A CN 103908465 A CN103908465 A CN 103908465A
- Authority
- CN
- China
- Prior art keywords
- parts
- zidovudine
- lamivudine
- substituted hydroxypropyl
- hydroxypropyl cellulose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960001627 lamivudine Drugs 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 34
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims abstract description 26
- 229960002555 zidovudine Drugs 0.000 claims abstract description 26
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims abstract description 25
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims abstract description 25
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 22
- 239000008101 lactose Substances 0.000 claims abstract description 22
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 18
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 18
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 18
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 18
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 17
- 239000002994 raw material Substances 0.000 claims abstract description 5
- 239000007864 aqueous solution Substances 0.000 claims abstract description 3
- 239000008187 granular material Substances 0.000 claims description 28
- 235000007164 Oryza sativa Nutrition 0.000 claims description 23
- 235000009566 rice Nutrition 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 16
- 229960001375 lactose Drugs 0.000 claims description 9
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 239000008213 purified water Substances 0.000 claims description 4
- 239000007779 soft material Substances 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 238000003556 assay Methods 0.000 claims description 2
- 240000007594 Oryza sativa Species 0.000 claims 1
- 241000209094 Oryza Species 0.000 description 22
- 238000004090 dissolution Methods 0.000 description 14
- 239000003814 drug Substances 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- 241000725303 Human immunodeficiency virus Species 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 208000030507 AIDS Diseases 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 229940080431 lamivudine 150 mg Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940102247 zidovudine 300 mg Drugs 0.000 description 2
- LHCOVOKZWQYODM-CPEOKENHSA-N 4-amino-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one;1-[(2r,4s,5s)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1.O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 LHCOVOKZWQYODM-CPEOKENHSA-N 0.000 description 1
- 229940124321 AIDS medicine Drugs 0.000 description 1
- 206010061623 Adverse drug reaction Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000000798 anti-retroviral effect Effects 0.000 description 1
- 229940124522 antiretrovirals Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 239000008183 oral pharmaceutical preparation Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 229940048102 triphosphoric acid Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229940120938 zidovudine and lamivudine Drugs 0.000 description 1
Landscapes
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210598061.3A CN103908465B (zh) | 2012-12-29 | 2012-12-29 | 一种易于溶出的齐多拉米双夫定片及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210598061.3A CN103908465B (zh) | 2012-12-29 | 2012-12-29 | 一种易于溶出的齐多拉米双夫定片及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103908465A true CN103908465A (zh) | 2014-07-09 |
CN103908465B CN103908465B (zh) | 2016-05-11 |
Family
ID=51034669
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210598061.3A Active CN103908465B (zh) | 2012-12-29 | 2012-12-29 | 一种易于溶出的齐多拉米双夫定片及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103908465B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107334743A (zh) * | 2016-07-15 | 2017-11-10 | 安徽贝克生物制药有限公司 | 一种齐多夫定、拉米夫定、奈韦拉平复方片及其制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1241142A (zh) * | 1996-10-31 | 2000-01-12 | 葛兰素集团有限公司 | 含有拉米夫定和齐多夫定的药用组合物 |
CN1903183A (zh) * | 2006-07-28 | 2007-01-31 | 杨喜鸿 | 替比夫定分散片及其制备方法 |
CN101744785A (zh) * | 2008-12-03 | 2010-06-23 | 温州医学院 | 速释片剂及其制备方法 |
CN102247332A (zh) * | 2011-01-27 | 2011-11-23 | 济南久创化学有限责任公司 | 一种拉米夫定片及其制备方法 |
-
2012
- 2012-12-29 CN CN201210598061.3A patent/CN103908465B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1241142A (zh) * | 1996-10-31 | 2000-01-12 | 葛兰素集团有限公司 | 含有拉米夫定和齐多夫定的药用组合物 |
CN1903183A (zh) * | 2006-07-28 | 2007-01-31 | 杨喜鸿 | 替比夫定分散片及其制备方法 |
CN101744785A (zh) * | 2008-12-03 | 2010-06-23 | 温州医学院 | 速释片剂及其制备方法 |
CN102247332A (zh) * | 2011-01-27 | 2011-11-23 | 济南久创化学有限责任公司 | 一种拉米夫定片及其制备方法 |
Non-Patent Citations (1)
Title |
---|
肖威等: "口腔速释制剂制备工艺的研究进展", 《齐齐哈尔医学院学报》, vol. 30, no. 11, 31 December 2009 (2009-12-31), pages 1375 - 1376 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107334743A (zh) * | 2016-07-15 | 2017-11-10 | 安徽贝克生物制药有限公司 | 一种齐多夫定、拉米夫定、奈韦拉平复方片及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN103908465B (zh) | 2016-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102657629B (zh) | 替卡格雷缓释片系统及其制备方法 | |
CN103319479A (zh) | 大黄酸小檗碱离子对化合物、制备方法及应用 | |
CN101461790B (zh) | 一种拉米夫定片剂及制备方法 | |
CN104688700B (zh) | 一种易于溶出的富马酸替诺福韦二吡呋酯片及其制备方法 | |
CN104000789A (zh) | 一种阿德福韦酯分散片及其制备方法 | |
CN104586798A (zh) | 一种吉非替尼分散片及其制备方法 | |
CN102144984B (zh) | 一种易于溶出的拉米夫定片及其制备方法 | |
CN101199491A (zh) | 拉米夫定片及其制备方法 | |
CN105213335A (zh) | 格列吡嗪片剂及其制备方法与应用 | |
CN103908465B (zh) | 一种易于溶出的齐多拉米双夫定片及其制备方法 | |
CN102512387B (zh) | 扎西他滨药物组合物 | |
CN101069687A (zh) | 恩替卡韦分散片及其制备方法 | |
CN102988317A (zh) | 一种苯磺酸氨氯地平药物制剂及其制备方法 | |
CN103536577B (zh) | 富马酸替诺福韦二吡呋酯胶囊剂及其制备方法 | |
EP1673072A2 (en) | A controlled release pharmaceutical composition and a process for preparing the same | |
CN105213332A (zh) | 一种富马酸替诺福韦二吡呋酯的口服片剂及其制备方法 | |
CN101757019B (zh) | 用于减肥或治疗代谢综合征的药物组合物 | |
CN104086490A (zh) | 一种格列吡嗪化合物及含有该化合物的药物组合物及其制备方法 | |
CN103169728A (zh) | 抗艾滋病复方制剂及其制备方法 | |
CN101785781B (zh) | 一种左旋氨氯地平或其可药用盐和黑木耳多糖的药物组合物及其应用 | |
CN101467985B (zh) | 一种富马酸比索洛尔分散片及其制备方法 | |
CN106176761B (zh) | 一种包含单硝酸异山梨酯和伊伐布雷定的组合物的用途 | |
CN102258493A (zh) | 红景天苷缓释片及其制备方法 | |
CN114392239B (zh) | 一种拉米夫定、齐多夫定和依非韦伦的复方片及其制备方法 | |
CN107550880A (zh) | 茶碱24小时缓释片及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Zidovudine-lamivudine tablet easy to dissolve out and preparation method thereof Effective date of registration: 20170321 Granted publication date: 20160511 Pledgee: Bank of Dongguan Limited by Share Ltd Hefei branch Pledgor: Anhui Biochem Bio-Pharmaceutical Co., Ltd. Registration number: 2017340000039 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20180905 Granted publication date: 20160511 Pledgee: Bank of Dongguan Limited by Share Ltd Hefei branch Pledgor: Anhui Biochem Bio-Pharmaceutical Co., Ltd. Registration number: 2017340000039 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Zidovudine-lamivudine tablet easy to dissolve out and preparation method thereof Effective date of registration: 20190328 Granted publication date: 20160511 Pledgee: Hefei high tech Company limited by guarantee Pledgor: Anhui Biochem Bio-Pharmaceutical Co., Ltd. Registration number: 2019340000162 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20200722 Granted publication date: 20160511 Pledgee: Hefei high tech Company limited by guarantee Pledgor: Anhui Biochem Bio-Pharmaceutical Co.,Ltd. Registration number: 2019340000162 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: An easily soluble zidorami divodine tablet and its preparation method Effective date of registration: 20210322 Granted publication date: 20160511 Pledgee: China Construction Bank Co.,Ltd. Hefei government culture new area sub branch Pledgor: Anhui Biochem Bio-Pharmaceutical Co.,Ltd. Registration number: Y2021340000006 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |